A Postmarket Registry of the BioMatrix and BioMatrix Flex Drug Eluting Stents.

Trial Profile

A Postmarket Registry of the BioMatrix and BioMatrix Flex Drug Eluting Stents.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2015

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms eBMX-PMR
  • Sponsors Biosensors International Group
  • Most Recent Events

    • 06 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2016 to 1 Apr 2015.
    • 21 May 2013 New registry data were presented at EuroPCR 2013, according to a Biosensors International Group.
    • 02 Jan 2013 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top